{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:14:57Z","timestamp":1791216897478,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.euroneuro.2013.10.004","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T00:04:13Z","timestamp":1382054653000},"page":"181-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacological management of alcohol dependence: From mono-therapy to pharmacogenetics and beyond"],"prefix":"10.1016","volume":"24","author":[{"given":"Fabio","family":"Caputo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teo","family":"Vignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Grignaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cibin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Addolorato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.10.004_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000084161","article-title":"How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review","volume":"51","author":"Addolorato","year":"2005","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib3","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.addbeh.2004.12.011","article-title":"Neurobiochemical and clinical aspects of craving in alcohol addiction: a review","volume":"30","author":"Addolorato","year":"2005","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543780902905855","article-title":"The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data","volume":"18","author":"Addolorato","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose\u2013response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/alcalc\/33.5.465","article-title":"Gamma-hydroxybutyric acid reducing effect on ethanol intake: evidence in favour of a substitution mechanism","volume":"33","author":"Agabio","year":"1998","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s002130000607","article-title":"Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence","volume":"154","author":"Ait-Daoud","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","volume":"24","author":"Anton","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib10","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combine pharmacotherapies and behavioural intervention for alcohol dependence: the COMBINE study: a randomized controlled study","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of muopioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study","volume":"65","author":"Anton","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drugalcdep.2013.04.025","article-title":"Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption","volume":"133","author":"Aubin","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/archpsyc.1992.01820080007002","article-title":"Types of alcoholics, I. Evidence for an empirically derived typology based on indicator of vulnerability and severity","volume":"49","author":"Babor","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2012.00103","article-title":"Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients","volume":"3","author":"de Beaurepaire","year":"2012","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib98","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib17","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2174\/138161210791516468","article-title":"Medications acting on the GABA system in the treatment of alcoholic patients","volume":"16","author":"Caputo","year":"2010","journal-title":"Curr. Pharm. Des"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.euroneuro.2007.04.008","article-title":"Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study","volume":"17","author":"Caputo","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0269881108094620","article-title":"Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study","volume":"23","author":"Caputo","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.euroneuro.2010.12.005","article-title":"Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity","volume":"21","author":"Caputo","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.04.012","article-title":"Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse","volume":"104","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","article-title":"Association of \u03bc-opioid receptor (OPRM1) gene polymorfism with response to naltrexone in alcohol dependence: a systematic reviews and meta-analysis","volume":"17","author":"Chamorro","year":"2012","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","article-title":"Safety issues concerning the use of disulfiram in treating alcohol dependence","volume":"20","author":"Chick","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881111408463","article-title":"Substitution therapy for alcoholism: time for a reappraisal?","volume":"26","author":"Chick","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archpsyc.1981.01780330019001","article-title":"Inheritance of alcohol abuse. Cross-fostering analysis of adopted men","volume":"38","author":"Cloninger","year":"1981","journal-title":"Arch. Gen. Psych"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(94)00687-3","article-title":"Cross-tolerance to ethanol and gamma-hydroxybutyric acid","volume":"273","author":"Colombo","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/alcalc\/agp043","article-title":"Cognitive components of frontal lobe function in alcoholics classified according to Lesch's typology","volume":"44","author":"Da Penha Zago-Gomes","year":"2009","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2165\/00023210-200519060-00004","article-title":"Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action","volume":"19","author":"De Witte","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hup.1098","article-title":"Pregabalin in outpatients detoxification of subject with mild-to-moderate alcohol withdrawal syndrome","volume":"25","author":"Di Nicola","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/alcalc\/agr131","article-title":"Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series","volume":"46","author":"Dore","year":"2011","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00129785-200303040-00001","article-title":"Pharmacogenomics of alcohol response and addiction","volume":"3","author":"Enoch","year":"2003","journal-title":"Am. J. Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib31","unstructured":"European Medicines Agency (EMEA), 2010. Guideline on the Development of Medicinal Products for the Treatment of Alcohol Dependence. EMEA\/CHMP\/EWP\/20097\/2008."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMcp1204714","article-title":"Alcohol use in adults","volume":"368","author":"Friedmann","year":"2013","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib33","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib34","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence. A randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0741-8329(99)00091-9","article-title":"Mechanism of the anti-alcohol effect of gamma-hydroxybutyric acid (GHB)","volume":"20","author":"Gessa","year":"2000","journal-title":"Alcohol"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib36","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1176\/appi.ajp.160.4.636","article-title":"The endophenotype concept in psychiatry: etymology and strategic intentions","volume":"160","author":"Gottesman","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","author":"Gual","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s12325-012-0061-5","article-title":"Pregabalin for alcohol dependence. A critical review of the literature","volume":"29","author":"Guglielmo","year":"2012","journal-title":"Adv. Ther."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib39","series-title":"The Disease Concept of Alcoholism","author":"Jellinek","year":"1960"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib44","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/appi.ajp.2010.08101500","article-title":"Medication treatment of different types of alcoholism","volume":"167","author":"Johnson","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00213-002-1002-9","article-title":"Ondansetron reduces the craving of biologically predisposed alcoholics","volume":"160","author":"Johnson","year":"2002","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib42","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib43","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib46","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/appi.ajp.2013.12091163","article-title":"Determination of genotype combination that can predict the outcome of the treatment of alcohol dependence using 5-HT3 antagonist ondansetron","volume":"170","author":"Johnson","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib47","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study","volume":"31","author":"Karhuvaara","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib48","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2174\/138161211796150873","article-title":"Pharmacological treatments for cocaine dependence: is there something new?","volume":"17","author":"Karila","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/j.1369-1600.2012.00482.x","article-title":"Association of GATA4 sequence variation alcohol dependence","author":"Karpyak","year":"2012","journal-title":"Addict. Biol"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib50","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","article-title":"Nalmefene: a review of its use in the treatment of alcohol dependence","volume":"27","author":"Keating","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib51","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2174\/138161210791516396","article-title":"Medications acting on the serotonergic system for the treatment of alcohol dependent patients","volume":"16","author":"Kenna","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1369-1600.2007.00073.x","article-title":"Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone","volume":"13","author":"Kiefer","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib54","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/tpj.2010.51","article-title":"Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate","volume":"11","author":"Kiefer","year":"2011","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib55","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2174\/138161210791516431","article-title":"Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment","volume":"16","author":"Krampe","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib56","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1530-0277.2001.tb02356.x","article-title":"Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis","volume":"25","author":"Kranzler","year":"2001","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1369-1600.2012.00471.x","article-title":"Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment","volume":"18","author":"Kranzler","year":"2013","journal-title":"Addict. Biol"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib58","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1369-1600.2011.00337.x","article-title":"Successful deep brain stimulation of the nucleus accumbens in severe alcohol dependence is associated with changed performance monitoring","volume":"16","author":"Kuhn","year":"2011","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11065-008-9080-z","article-title":"Typologies of alcohol dependence. From Jellinek to genetics and beyond","volume":"19","author":"Leggio","year":"2009","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib60","first-page":"CD006266","article-title":"Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses","volume":"2","author":"Leone","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0379-0738(88)90225-3","article-title":"The course of alcoholism. Long-term prognosis in different subtypes","volume":"36","author":"Lesch","year":"1988","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF02255976","article-title":"The European acamprosate trials: conclusions for research and therapy","volume":"18","author":"Lesch","year":"2001","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib63","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the global burden of disease study, 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: a vision for the next decade","volume":"17","author":"Litten","year":"2012","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib65","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/alcalc\/agr083","article-title":"Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists","volume":"46","author":"Luquiens","year":"2011","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib66","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B\u204e5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib67","article-title":"Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study","author":"Mann","year":"2012","journal-title":"Addict. Biol"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib68","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib69","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/ijerph8072816","article-title":"Long-term \u03b3-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics","volume":"8","author":"Maremmani","year":"2011","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib71","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1517\/13543784.2012.703179","article-title":"Pregabalin in clinical psychiatry and addiction: pros and cons","volume":"21","author":"Martinotti","year":"2012","journal-title":"Exp. Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib70","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hup.833","article-title":"High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patient","volume":"22","author":"Martinotti","year":"2007","journal-title":"Hum. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib72","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.comppsych.2013.03.023","article-title":"Craving Typology Questionnaire (CTQ): a scale for alcohol craving in normal controls and alcoholics","volume":"54","author":"Martinotti","year":"2013","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib75","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1530-0277.2011.01616.x","article-title":"Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data","volume":"36","author":"Mason","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib73","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","volume":"18","author":"Mason","year":"1994","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib74","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib76","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1037\/0022-006X.65.5.768","article-title":"Affiliation with alcoholics anonymous after treatment: a study of its therapeutic effects and mechanisms of action","volume":"65","author":"Morgenstern","year":"1997","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/WNF.0b013e3182216fd5","article-title":"Experienced acetaldehyde reaction does not improve treatment response in outpatients treated with supervised disulfiram","volume":"34","author":"Mutschler","year":"2011","journal-title":"Clin. Neuropharm."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib78","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1017\/S1461145711001040","article-title":"Auditory event-related potentials (P3) and cognitive changes induced by frontal direct current stimulation in alcoholics according to Lesch alcoholism typology","volume":"15","author":"Nakamura-Palacios","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(00)00191-5","article-title":"GHB: a new and novel drug of abuse","volume":"63","author":"Nicholson","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib80","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","article-title":"A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients","volume":"28","author":"Oslin","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib81","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2165\/00023210-200620120-00004","article-title":"Gamma-hydroxybutyrate\/GHB: neurobiology, and impact on sleep and wakefulness","volume":"20","author":"Pardi","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib82","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders","volume":"57","author":"Petrakis","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib83","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.biopsych.2006.03.074","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and comorbid post traumatic stress disorder","volume":"60","author":"Petrakis","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib84","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/schbul\/sbl010","article-title":"Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram","volume":"32","author":"Petrakis","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib85","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/jcp.0b13e3180337fcb","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and current depression","volume":"27","author":"Petrakis","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/alcalc\/agn080","article-title":"The alcoholic phenotypes among different multidimensional typologies: similarities and their classification procedures","volume":"44","author":"Pombo","year":"2009","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib87","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib88","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib89","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","volume":"8","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib90","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","volume":"8","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib91","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/109493103322278790","article-title":"Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project","volume":"6","author":"Schifano","year":"2003","journal-title":"Cyberpsychol. Behav."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib92","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","article-title":"Alcohol-use disorders","volume":"373","author":"Schuckit","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib93","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1530-0277.1994.tb00054.x","article-title":"Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence","volume":"18","author":"Sellers","year":"1994","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib94","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/alcalc\/34.2.223","article-title":"Craving for alcohol: findings from the clinic and the laboratory","volume":"34","author":"Sinha","year":"1999","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib95","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1369-1600.2010.00287.x","article-title":"Pharmacogenetics of alcohol, nicotine, and drug addiction treatments","volume":"16","author":"Sturgess","year":"2011","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib96","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2146\/ajhp060644","article-title":"Emerging approaches to managing alcohol dependence","volume":"64","author":"Swift","year":"2007","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib97","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0641-7","article-title":"Accumbens neurochemical adaptations produced by binge-like alcohol consumption","volume":"190","author":"Szumlinski","year":"2007","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.euroneuro.2013.10.004_bib99","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/alcalc\/34.2.197","article-title":"A three-pathway psychological model of craving for alcohol","volume":"34","author":"Verheul","year":"1999","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2013.10.004_bib100","unstructured":"World Health Organisation (WHO), 2000. International Guide for Monitoring Alcohol Consumption and Related Harm. WHO\/MSD\/MSB\/00.4."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13002964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13002964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T23:25:00Z","timestamp":1539300300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13002964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0924977X13002964"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.10.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological management of alcohol dependence: From mono-therapy to pharmacogenetics and beyond","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}